The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry.
 
Edoardo Francini
Travel, Accommodations, Expenses - Janssen-Cilag
 
Kathryn P. Gray
Stock and Other Ownership Interests - MDGN
 
Grace Shaw
No Relationships to Disclose
 
Carolyn Evan
No Relationships to Disclose
 
Anis Hamid
Travel, Accommodations, Expenses - Amgen Astellas BioPharma; Bayer
 
Caitlin E Perry
No Relationships to Disclose
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Druggablity Technologies; Placon; Tarveda Therapeutics
Consulting or Advisory Role - Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Druggablity Technologies; Genentech/Roche; GTx; Ipsen; Janssen; Merck; Metamark Genetics; MorphoSys; MTG Therapeutics; Omnitura; OncoCellMDX; Oncogenex; Progenity; Sanofi; Tarveda Therapeutics; Thermo Fisher Scientific
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Expert Testimony - Janssen; Sanofi
Travel, Accommodations, Expenses - Sanofi; Tarveda Therapeutics
 
Mary-Ellen Taplin
Honoraria - Bayer; Clovis Oncology; Janssen-Ortho; Medivation
Consulting or Advisory Role - Bayer; Best Doctors, Inc; Clovis Oncology; Dava Oncology; Guidepoint Global; Janssen-Ortho; Medivation; Myovant Sciences; Research to Practice; Sanofi; UpToDate
Research Funding - Bayer (Inst); Genentech (Inst); Janssen-Ortho (Inst); Medivation (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Medivation; Tokai Pharmaceuticals
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen Biotech (Inst); Sanofi (Inst); Sotio (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination